Abstract
Background:Osteogenesis imperfecta (OI) is characterized by bone fragility and short stature. Data about IGF-I/IGFBP-3 levels are rare in OI. Therefore IGF-I/IGFBP-3 levels in children with different types of OI were investigated.
Methods: IGF-I and IGFBP-3 levels of 60 children (male n=38) were assessed in a retrospective cross-sectional setting.
Results: Height/weight was significant different [height z-score type 3 versus type 4: p=0.0011 and weight (p≤0.0001)] between OI type 3 and 4. Mean IGF-I levels were in the lower normal range (mean±SD level 137.4±109.1 μg/L). Mean IGFBP-3 measurements were in the normal range (mean±SD 3.105±1.175 mg/L). No significant differences between OI type 3 and 4 children have been observed (IGF-I: p=0.0906; IGFBP-3: p=0.2042).
Conclusions: Patients with different severities of OI have IGF-I and IGFBP-3 levels in the lower normal range. The type of OI does not significantly influence these growth factors.
Acknowledgments
The authors would like to express their gratitude to the patients which are cared for by our staff. We thank Monika Kron and Angelika Stabrey for invaluable administrative support.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. The corresponding author confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Research funding: We thank “Deutsche Gesellschaft für Osteogenesis imperfecta (Glasknochen) Betroffene e.v.” including “Stiftung Baden-Württemberg” for financial research support.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363:1377–85.10.1016/S0140-6736(04)16051-0Search in Google Scholar
2. Marini JC, Blissett AR. New genes in bone development: what’s new in osteogenesis imperfecta. J Clin Endocrinol Metab 2013;98:3095–103.10.1210/jc.2013-1505Search in Google Scholar
3. Ben Amor IM, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos 2011;2011:540178.10.4061/2011/540178Search in Google Scholar
4. Sillence DO. Osteogenesis imperfecta nosology and genetics. Ann N Y Acad Sci 1988;543:1–15.10.1111/j.1749-6632.1988.tb55311.xSearch in Google Scholar
5. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111(5 Pt 1):1030–6.10.1542/peds.111.5.1030Search in Google Scholar
6. Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996;129:432–9.10.1016/S0022-3476(96)70077-XSearch in Google Scholar
7. Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975;7:488–91.10.1055/s-0028-1093710Search in Google Scholar PubMed
8. Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 1993;45:261–4.10.1002/ajmg.1320450223Search in Google Scholar PubMed
9. Marini JC, Bordenick S, Heavner G, Rose S, Hintz R, et al. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 1993;76:251–6.Search in Google Scholar
10. Wright NM. Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis. J Pediatr Endocrinol Metab 2000;13(Suppl 2):999–1002.Search in Google Scholar
11. Blum WF, Cao D, Hesse V, Fricke-Otto S, Ross JL, et al. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome. Horm Res 2009;71:167–72.10.1159/000197874Search in Google Scholar PubMed
12. Land C, Blum WF, Stabrey A, Schoenau E. Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency. Eur J Endocrinol 2005;152:727–33.10.1530/eje.1.01899Search in Google Scholar PubMed
13. Hindmarsh PC, Dattani MT. Use of growth hormone in children. Nat Clin Pract Endocrinol Metab 2006;2:260–8.10.1038/ncpendmet0169Search in Google Scholar PubMed
14. Poidvin A, Touze E, Ecosse E, Landier F, Bejot Y, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology 2014;83:780–6.10.1212/WNL.0000000000000737Search in Google Scholar PubMed
15. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005;20:758–63.10.1359/JBMR.041232Search in Google Scholar PubMed
16. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80–101.10.1210/edrv-15-1-80Search in Google Scholar PubMed
17. Veilleux LN, Lemay M, Pouliot-Laforte A, Cheung MS, Glorieux FH, et al. Muscle anatomy and dynamic muscle function in osteogenesis imperfecta type I. J Clin Endocrinol Metab 2013;99:E356–62.10.1210/jc.2013-3209Search in Google Scholar PubMed
18. Bikle DD, Tahimic C, Chang W, Wang Y, Philippou A, et al. Role of IGF-I signaling in muscle bone interactions. Bone 2015;80:79–88.10.1016/j.bone.2015.04.036Search in Google Scholar PubMed PubMed Central
19. Frost HM, Schonau E. The “muscle-bone unit” in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 2000;13:571–90.10.1515/JPEM.2000.13.6.571Search in Google Scholar
20. Wu QQ, Chen Q. Mechanoregulation of chondrocyte proliferation, maturation, and hypertrophy: ion-channel dependent transduction of matrix deformation signals. Exp Cell Res 2000;256:383–91.10.1006/excr.2000.4847Search in Google Scholar PubMed
©2016 by De Gruyter
